ZhiBin Wang

Dr. ZhiBin Wang


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YGYuan-Feng Gao
Yuan-Feng Gao
TZTao Zhu
Tao Zhu
CMChenxue Mao
Chenxue Mao
Zhixiong LiuZhixiong Liu
Zhixiong Liu
ZWZhiBin Wang
ZhiBin Wang
ZLZhao-Qian Liu
Zhao-Qian Liu
Current treatment methods for patients diagnosed with gliomas have shown limited success. This is partly due to the lack of prognostic genes available to accurately predict disease outcomes. The aim of this study was to investigate novel prognostic genes based on the molecular profile of tumor samples and their correlation with clinical parameters. In the current study, microarray data (GSE4412 and GSE7696) downloaded from Gene Expression Omnibus were used to identify differentially expressed prognostic genes (DEPGs) by significant analysis of microarray (SAM) between long-term survivors (>2 years) and short-term survivors (≤2 years). DEPGs generated from these two datasets were intersected to obtain a list of common DEPGs. The expression of a subset of common DEPGs was then independently validated by real-time reverse transcription quantitative PCR (qPCR). Survival value of the common DEPGs was validated using known survival data from the GSE4412 and TCGA dataset. After intersecting DEPGs generated from the above two datasets, three genes were identified which may potentially be used to determine glioma patient prognosis. Independent validation with glioma patients tissue (n = 70) and normal brain tissue (n = 19) found PPIC, EMP3 and CHI3L1 were up-regulated in glioma tissue. Survival value validation showed that the three genes correlated with patient survival by Kaplan-Meir analysis, including grades, age and therapy.

8 August 2025 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
SJShi-Long Jiang
Shi-Long Jiang
DWDong Wang
Dong Wang
CZChan Zou
Chan Zou
ZZZe-Wu Zhu
Ze-Wu Zhu
CLChao Luo
Chao Luo
ZWZhiBin Wang
ZhiBin Wang

29 December 2025 in Metabolism
Verified
Journal Article
Closed access
DLDe-Hua Liao
De-Hua Liao
SJShi-Long Jiang
Shi-Long Jiang
TWTing Wu
Ting Wu
ZCZeng Cao
Zeng Cao
ZZZe-Wu Zhu
Ze-Wu Zhu
ZWZhiBin Wang
ZhiBin Wang

29 January 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
ZWZhiBin Wang
ZhiBin Wang
MLMing-Hui Long
Ming-Hui Long
PYPing Yu
Ping Yu
YWYa-Li Wang
Ya-Li Wang
ZYZheng Yang
Zheng Yang
MHMasha Huang
Masha Huang
Ovarian cancer remains a lethal disease marked by profound therapeutic resistance, largely orchestrated by a complex tumor microenvironment (TME) governed by metabolism-immune crosstalk. This review focuses on the spatiotemporal dynamics of the metabolism-immune axis in ovarian cancer progression and resistance, with particular emphasis on how cutting-edge spatial multi-omics technologies reveal previously unrecognized layers of intratumoral heterogeneity and geographic organization that cannot be captured by bulk analyses. Using tools such as MALDI-MSI, GeoMx DSP, and CODEX, these approaches enable high-resolution, spatially resolved mapping of metabolite gradients (e.g., lactate, lipids, kynurenine), immune cell niches, and immunometabolic checkpoints within distinct tumor regions. Such spatial profiling uncovers how metabolic reprogramming-dysregulated glycolysis, lipid metabolism, and glutaminolysis-drives localized immunosuppression and chemoresistance through compartment-specific interactions among tumor cells, cancer-associated fibroblasts (CAFs), adipocytes, and immune populations. These geographically defined insights reshape our understanding of therapeutic failure and highlight precise, location-aware vulnerabilities. Accordingly, we propose spatially informed therapeutic strategies, including regional glycolysis inhibition, glutaminase blockade, lipid pathway interference, and their rational combination with immune checkpoint inhibitors (ICIs), to disrupt pathogenic metabolic-immune circuits and improve immunotherapy outcomes. Looking ahead, advances in vivo spatial imaging, gut microbiota modulation, and AI-powered integrative multi-omics frameworks promise truly personalized treatment of ovarian cancer.

19 June 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
QLQianjin Liao
Qianjin Liao
ZWZhiBin Wang
ZhiBin Wang
SCSilvia Maria Suter Correia Cadena
Silvia Maria Suter Correia Cadena
Editorial: Targeting oxidative stress in cancer: what is new in the prevention, diagnostic, treatment and prognostic strategies?